Browse by Vaccine Type

This page shows data for Protein subunit vaccine type.
Total Entries Retrieved: 54
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10007 Abdala COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Center for Genetic Engineering and Biotechnology 2021 Cuba 19 - 80 years NA Intramuscular Aluminum (aluminium hydroxide) NA NA Cuba Drug Regulator NA Cuba, Venezuela CIGB-66 NA NA https://rpcec.sld.cu/en/trials/RPCEC00000363-En https://rpcec.sld.cu/en/trials/RPCEC00000359-En
10011 Zifivax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. 2020 China NA 2 doses 2 to 3 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA China FDA Institute of Microbiology of the Chinese Academy of Sciences China, Uzbekistan, Indonesia, Pakistan, Ecuador RBD-Dimer, ZF2001 33816047 NCT04646590 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05091411
10030 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Novavax Inc. NA UK NA 2 doses Intramuscular Matrix-M Spike protein of SARS-CoV-2 virus NA US FDA NA USA, Mexico TAK-019, SARS-CoV-2 rS, NVX-CoV2373 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://clinicaltrials.gov/ct2/show/NCT05249816
10033 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved FBRI State Research Center of Virology and Biotechnology 2020 Russia 18 years and above 2 doses 21 days apart Intramuscular Aluminum (aluminium hydroxide) SARS CoV-2 peptide antigens NA Russian Federation FBRI State Research Center of Virology and Biotechnology NA EpiVacCorona-N, Aurora-CoV 33816047 NCT04780035 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html
10034 MVC-COV1901 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Medigen Vaccine Biologics, Dynavax 2021 Taiwan 12 years and above 2 doses 28 days apart Intramuscular CpG 1018, aluminium hydroxide S-2P protein NA Taiwan FDA National Institute of Allergy and Infectious Diseases Thailand, Taiwan, Paraguay NA 33816047 NCT05198596 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.precisionvaccinations.com/vaccines/medigen-covid-19-vaccine
10039 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Novavax Inc. 2021 USA 12 years and above 2 doses 21 days apart Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA WHO NA USA, Mexico, Puerto Rico, UK NVX-CoV2373 33402220 NCT04611802 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://www.drugs.com/history/novavax-covid-19-vaccine.html
10040 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved FBRI State Research Center of Virology and Biotechnology 2021 Russia 18 - 60 years 2 doses 21 or 28 days apart Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 protein NA Russian Federation FBRI State Research Center of Virology and Biotechnology Cambodia, Russia, Turkmenistan EpiVacCorona-N, Aurora-CoV 33402220 NCT04780035 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://clinicaltrials.gov/ct2/show/NCT04780035
10054 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Vector State Research Centre of Viralogy and Biotechnology NA Russia NA NA Intramuscular NA NA NA Russian Federation NA Russia, Cambodia EpiVacCorona-N, Aurora-CoV NA NCT04780035 https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine#:~:text=EpiVacCorona%20(Aurora%2DCoV)%20is,19%20and%20promotes%20immunity%20development.
10055 Zifivax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. NA China NA NA Intramuscular NA NA Recombinant UAE NA NA Recombinant Novel Coronavirus Vaccine CHO Cell) NA NCT04550351 https://clinicaltrials.gov/ct2/show/NCT04550351 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04646590
10056 Pasteur COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved BioCubaFarma 2021 Cuba NA NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA CECMED NA NA FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02 NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://rpcec.sld.cu/trials/RPCEC00000354-En
10058 TAK-019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Takeda Pharmaceutical Company Limited 2021 USA 20 years and above 2 doses 21 days apart Intramuscular NA NA NA US FDA, Japan MHLW NA Indonesia, Philippines, Japan NA NA NCT05299359 https://clinicaltrials.gov/ct2/show/NCT05299359 NA
10102 RECOMBIVAX HB Hepatitis B Hepatitic Hepatitis B virus double stranded DNA Protein subunit Approved Merck & Co. Inc. NA USA All age group 2 doses 6 months apart Intramuscular NA HBsAg NA US FDA NA NA NA NA NA https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ https://www.fda.gov/vaccines-blood-biologics/vaccines/recombivax-hb
10147 CoV2-OGEN1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Specialty Formulations, VaxForm LLC. 2021 New Zealand 18 - 56 years 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04893512 https://clinicaltrials.gov/show/NCT04893512 NA
10149 OSE13E COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 OSE Immunotherapeutics 2021 Belgium 18 - 45 years 2 doses 21 days apart Subcutaneous NA 11 different proteins of SARS-CoV-2 virus NA NA NA NA CoVepiT NA NCT04885361 https://clinicaltrials.gov/show/NCT04885361 NA
10151 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Novavax Inc. NA NA NA NA Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ https://clinicaltrials.gov/ct2/show/NCT04368988
10169 AdimrSC-2f COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Adimmune Corporation 2021 Taiwan 20 - 60 years NA Intramuscular Aluminum Recombinant receptor binding domain of SARS-CoV-2 spike protein NA NA NA NA NA 33816047 NCT04522089 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05104489
10170 Shingrix COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 University of Oklahoma  NA NA NA 2 doses 60 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10176 Noora vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Bagheiat-allah University of Medical Sciences 2021 Iran 18 - 50 years 3 doses on day 0, 21 and 35 Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA AmitisGen NA NA https://en.irct.ir/trial/56987 NA
10177 COVAX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Vaxine, Medytox NA NA NA Single dose Intramuscular NA NA NA NA NA NA COVID-19 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10178 SpFN COVID-19 Vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Army Medical Research and Development Command 2021 USA 18 - 55 years 3 doses on day 1, 29 and 181 Intramuscular Army Liposomal Formulation QS21 Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04784767 https://clinicaltrials.gov/show/NCT04784767 NA
10182 ReCOV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Jiangsu Rec-Biotechnology Co. Ltd. 2021 New Zealand 18 - 60 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04818801 https://clinicaltrials.gov/ct2/show/NCT04818801 NA
10183 NBP2001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 SK Bioscience Co. Ltd. 2021 South Korea 19 - 55 years 2 doses 28 days apart Intramuscular MF59 SARS CoV-2 Receptor Binding domain NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/show/NCT04760743 NA
10188 Covax-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 GeneCure Biotechnologies 2020 USA 18 - 60 years 2 doses 2 weeks apart Intramuscular NA NA NA US FDA NA NA NA NA NCT04428073 https://clinicaltrials.gov/show/NCT04428073 https://delta.larvol.com/Products/bac627c1e3c7453f9c3e06990d38d930/COVAX19GC004/0/11eb4d064c904d80ad7af09be3dfc6e8/COVAX19-Monovalent-Recombinant-COVID19-Vaccine/
10239 QazCoVac-P COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Research Institute for Biological Safety Problems 2021 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04930003 https://clinicaltrials.gov/show/NCT04930003 NA
10241 S-268019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shionogi Inc. 2021 Japan 20 - 64 years NA Intramuscular NA NA NA NA NA NA NA NA NA https://jrct.niph.go.jp/en-latest-detail/jRCT2051200092 NA
10242 V-01 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Livzon Mabpharm Inc. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Recombinant SARS-CoV-2 fusion protein NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=124702 NA
10245 SpikoGen COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 CinnaGen Company 2021 Iran 18 years and above 2 doses 21 days apart Intramuscular Advax-CpG Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NA http://en.irct.ir/trial/56287 NA
10246 SII B.1.617.2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Novavax Inc. 2021 Australia 18 - 64 years 2 doses 21 days apart Intramuscular Matrix-M1 Bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent) NA NA NA NA NA NA NCT05029856 https://clinicaltrials.gov/ct2/show/NCT05029856 NA
10247 SCB-2020S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Clover Biopharmaceuticals 2021 Australia 18 - 75 years 2 doses 22 days apart Intramuscular AS03, CpG 1018, alum SARS-CoV-2(B.1.351 variant) trimeric spike protein NA NA NA NA NA NA NCT04950751 https://www.clinicaltrials.gov/ct2/show/NCT04950751 NA
10255 KBP-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Kentucky Bioprocessing Inc 2021 USA 18 - 85 years 2 doses 21 days apart Intramuscular CpG 1018 SARS-CoV-2 receptor-binding domain from spike protein NA US FDA NA NA NA 33816047 NCT04473690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10257 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Sanofi Pasteur, GlaxoSmithKline NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Baculovirus production NA NA NA VAT00002, VAT00008, SARS-CoV-2 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10266 Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 National Vaccine and Serum Institute 2021 China 3 years and above NA Intramuscular NA NA NA NA NA NA NA NA NCT04869592 https://clinicaltrials.gov/ct2/show/NCT05069129 NA
10267 PHH-1V COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Laboratorios HIPRA SA 2021 Spain 18 - 39 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA COVID-19 subunit vaccine NA NCT05007509 https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000074-25/ES NA
10268 COVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Vaccine and Infectious Disease Organization 2021 Canada 18 years and above 2 doses 28 days apart Intramuscular SWE Spike protein of SARS-CoV-2 virus NA NA Vaccine Formulation Institute NA NA NA NCT04702178 https://clinicaltrials.gov/ct2/show/NCT04702178 NA
10269 CoVac-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Hospital Tuebingen 2021 Germany 18 years and above Single dose Subcutaneous NA SARS-CoV-2 HLA-DR peptides NA NA NA NA IMP 33816047 NCT04954469 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10271 Pasteur COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Instituto Finlay de Vacunas 2021 Cuba NA 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02, Soberana 2 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10272 MF59 adjuvanted SARS-CoV-2 Sclamp vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University of Queensland 2021 Australia 18 years and above 2 doses 28 days apart Intramuscular MF59 Spike protein of SARS-CoV-2 virus NA NA NA NA SARS-CoV-2 Sclamp 33816047 NCT04495933 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10276 EuCorVac-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 EuBiologics Co. Ltd. 2021 South Korea 19 - 75 years 2 doses 3 weeks apart Intramuscular NA NA NA NA NA NA NA NA NCT04783311 https://clinicaltrials.gov/show/NCT04783311 NA
10278 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 United Biomedical Inc. 2021 China 12 - 85 years 2 doses Intramuscular NA NA NA NA NA NA NA NA NCT04773067 https://clinicaltrials.gov/show/NCT04773067 https://clinicaltrials.gov/ct2/show/NCT04683224
10281 AKS-452 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Medical Center Groningen 2021 Netherlands 18 - 65 years NA Subcutaneous NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04681092 https://clinicaltrials.gov/show/NCT04681092 NA
10288 ZR-202-CoV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shanghai Zerun Biotechnology, Walvax Biotechnology, CEPI 2021 China 18 years and above 2 doses 28 days apart Intramuscular CpG, alum SARS-CoV-2 protein NA NA NA NA NA NA NCT04990544 https://clinicaltrials.gov/ct2/show/NCT05313022 NA
10314 Nanocovax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Nanogen Pharmaceutical Biotechnology JSC 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04922788 https://clinicaltrials.gov/show/NCT04922788 NA
10319 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 3 doses on day 0, 21 and 42 Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04887207 https://clinicaltrials.gov/show/NCT04887207 https://clinicaltrials.gov/ct2/show/NCT04530656
10326 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. NA NA NA 2 doses 21 days apart Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10337 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals 2021 Australia 18 years and above 2 doses 21 days apart Intramuscular AS03, CpG 1018, alum Spike protein of SARS-CoV-2 virus NA NA GlaxoSmithKline, Dynavax NA NA 33816047 NCT04672395 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10339 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Vaxxinity 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10340 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10343 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur, GlaxoSmithKline 2021 USA 18 years and above 2 doses 14 days apart Intramuscular NA SARS-CoV-2 protein NA NA GlaxoSmithKline USA, Colombia, Honduras, Japan, Kenya VAT00002, VAT00008 NA NCT04904549 https://clinicaltrials.gov/ct2/show/NCT04904549 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10345 CoV2 preS dTM-AS03 vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur NA NA NA NA Intramuscular NA NA Recombinant EMA NA NA NA NA NCT04904549 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04762680
10346 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals NA Australia NA NA Intramuscular NA NA Novel recombinant SARSCoV-2 Spike trimer fusion protein NA NA Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland NA NA NCT04405908 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04405908
10349 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur 2021 USA 18 years and above 2 doses 21 days apart Intramuscular AS03 SARS-CoV-2 protein NA US FDA GlaxoSmithKline NA VAT00002, VAT00008 NA NCT04762680 https://clinicaltrials.gov/show/NCT04762680 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10350 Skycovion COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 SK Bioscience Co. Ltd. 2021 South Korea 19 - 85 years 2 doses 28 days apart Intramuscular AS03 Recombinant SARS-CoV-2 protein NA NA International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations NA GBP510 NA NCT04750343 https://clinicaltrials.gov/show/NCT04750343 NA
10352 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. 2020 Australia 18 - 59 years 2 doses 21 days apart Intramuscular NA NA NA US FDA NA NA TAK-019, SARS-CoV-2 rS NA NCT04368988 https://clinicaltrials.gov/show/NCT04368988 https://clinicaltrials.gov/ct2/show/NCT04368988
10360 Motavizumab Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA Protein subunit Phase 3 MedImmune LLC 2013 USA upto 1 year 5 doses in interval for 1 month Intramuscular NA Fusion glycoprotein of RSV NA NA NA NA NA NA NCT00129766 https://clinicaltrials.gov/ct2/show/NCT00129766?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=3 NA